Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

Gilead Sciences, Inc. (GILD) and GSK (GSK) are pioneers in the human immunodeficiency virus (HIV) treatment space.Gilead Sciences is a dominant player in the HIV market with market-leading treatments. HIV drug sales accounted for 69% of total product sales in the first quarter of 2025. GILD’s diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases.GSK, too, has a strong HIV portfolio in the industry. HIV drug sales accounted for 23% of total sales in the fi ...